A Retrospective Cohort Study to Evaluate Real-World Clinical Outcomes of Semaglutide on Glycemic Control and Weight as an Add-on to Treatment or Changed-On From Other GLP-1 in Patients with T2D who Initiate Treatment
Latest Information Update: 23 Jul 2020
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Jul 2020 New trial record
- 16 Jun 2020 Primary endpoint (Change from baseline in glycated Hb (HbA1c) at week 24) has been met, according to results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.